If left untreated chronic hepatitis can lead topermanent liver damage which can result in the development of liver

If left untreated, chronic hepatitis can lead topermanent liver damage, which can result in the development of liver cancer,liver failure or death. High safety margins have beenestablished in both single ascending dose and repeat dose studies in vivo.Overall, Achillion believes the compound is well tolerated with minimal sideeffects.About HCVThe hepatitis C virus (HCV) is the most common cause of viral hepatitis, whichis an inflammation of the liver. ACH-1625 has shownlow single-digit nanomolar potency that is specific to HCV. It is equipotentagainst HCV genotypes 1a and 1b at IC50 ~1nM. In preclinical studies ACH-1625 hasdemonstrated potency, unique pharmacokinetic properties and a safe in vivoprofile even at very high doses.With its rapid and extensive partitioning to the liver, as well as highliver/plasma ratios demonstrated in vivo, Achillion believes that ACH-1625 canbe dosed on a convenient schedule at a relatively low dosage. “With its potency and safety profile inpreclinical studies, and its potential for once-daily dosing, we are eager toadvance what we hope will be a best-in-class candidate.”About ACH-1625ACH-1625 is an HCV protease inhibitor designed and synthesized based on crystalstructures of enzyme/inhibitor complex. ACH-1625 is an open chain, non-covalent,reversible inhibitor of NS3 protease.

Kishbauch, President and ChiefExecutive Officer of Achillion. We believe ACH-1625 has thepotential to offer a convenient dosing schedule and an improved safety andtolerability profile compared to currently available treatments for HCV-infectedpatients.”"We are very excited to take ACH-1625 into the clinic to test the compound’ssafety and efficacy in humans,” said Michael D. “Importantly, it will alsoprovide Achillion with preliminary efficacy data and important dose selectioninformation for subsequent Phase II trials. Data fromthe trial are anticipated to be announced later this year.ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzymenecessary for viral replication.

The drug candidate was discovered and is beingadvanced by Achillion.”This first-in-human clinical trial will be instrumental in establishing thesafety profile of ACH-1625 in humans,” stated Elizabeth A. Olek, D.O., VicePresident and Chief Medical Officer of Achillion. The trial will take place in Europe and is designed to enroll 54subjects including both healthy volunteers and HCV-infected patients. (Nasdaq:ACHN), a leader in the discovery and development of small moleculedrugs to combat the most challenging infectious diseases, today announced thatthe Company has begun dosing in a Phase I clinical trial of ACH-1625, a proteaseinhibitor for the treatment of hepatitis C virus (HCV) infection.The Phase I clinical trial is a randomized, double-blind, placebo-controlledtrial to investigate the safety, tolerability, pharmacokinetic profile andantiviral activity of ACH-1625 after single and multiple ascending oral doses inhealthy volunteers, and oral ascending repeat doses in subjects with hepatitis Cinfection. The Equicom GroupDave Mason416-815-0700 ext. Copyright 2009, Market Wire, All rights reserved.-0-.

Achillion Announces First-in-Human Dosing of ACH-1625 for Treatment of HepatitisCNEW HAVEN, Conn., June 29, 2009 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals,Inc. Neither TSX Venture Exchange nor its Regulation Services Provider (asthat term is defined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.Contacts:GuestLogix Inc.Josef ZankowiczVP Marketing & Investors:The Equicom GroupKristen Dickson416-815-0700 ext. GuestLogix assumes no obligation to update theforward-looking statements, or to update the reasons why actual resultscould differ from those reflected in the forward-looking statements. These forward-lookingstatements are subject to a number of risks and uncertainties that couldcause actual results or events to differ materially from currentexpectations, including the matters discussed under “Risks andUncertainties” in the Filing Statement filed on June 29, 2009 with theregulatory authorities. The forward-lookingstatements are not historical facts, but reflect GuestLogix’ currentexpectations regarding future results or events. Any statements contained herein that are notstatements of historical facts may be deemed to be forward-looking,including those identified by the expressions “anticipate”, “believe”,”plan”, “estimate”, “expect”, “intend”, and similar expressions to theextent they relate to the Company or its management.

All other trademarks andtrade names are the property of their respective owners.Forward-Looking StatementsThis news release includes certain forward-looking statements that arebased upon current expectations, which involve risks and uncertaintiesassociated with GuestLogix’ business and the environment in which thebusiness operates. With a customer base comprising seven of the top 10 globalairlines GuestLogix maintains contracts to serve more than 30 per cent ofthe world airline passenger traffic through its proprietary platform.Additional information on the Company can be found at guestlogix andontouch .Copyright 2009 GuestLogix All Rights Reserved. Through its industry standardonboard transaction processing platform, the Company provides carriersthe tools to become successful onboard retailers and by way of itsOnTouch(TM) merchandising division it facilitates innovative products andservices to enhance passenger experience and propel ancillary revenuegrowth. Thereplay will also be available at (1) See GuestLogix’ MD&A and Financial Statement filed on June 29, 2009,for complete definition.About GuestLogixGuestLogix is the leading provider of onboard retail technology andsolutions to the passenger travel industry. To access the archived conference call, dial416-640-1917 or 1-877-289-8525 and enter reference number 21308371#.